AdeliKHigginsVNieuwesteegMRaizmanJEChenYWongSL, et al. Biochemical marker reference values across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. Clin Chem. 2015;61(8):1049-1062.
2.
SoldinOPBierbowerLHChoiJJChoiJJThompson-HoffmanSSoldinSJ. Serum iron, ferritin, transferrin, total iron binding capacity, hs-CRP, LDL cholesterol and magnesium in children; new reference intervals using the Dade Dimension Clinical Chemistry System. Clin Chim Acta. 2004;342(1-2):211-217.
3.
Grote BeverborgNVerweijNKlipITvan der WalHHVoorsAAvan VeldhuisenDJ, et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLOS ONE. 2015;10(4):e0125215.
4.
WiesenerMSSeyfarthMWarneckeCJürgensenJSRosenbergerCMorganNV, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood. 2002;99(10):3562-3565.
5.
GordeukVRSergueevaAIMiasnikovaGYOkhotinDVoloshinYChoykePL, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood. 2004;103(10):3924-3932.
6.
KralovicsRIndrakKStopkaTBermanBWPrchalJFPrchalJT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood. 1997;90:2057-2061.
7.
PercyMJLeeFS. Familial erythrocytosis: molecular links to red blood cell control. Haematologica. 2008;93(7):963-967.
TefferiARumiEFinazziGGisslingerHVannucchiAMRodeghieroF, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-1881.
10.
ScottLMTongWLevineRLScottMABeerPAStrattonMR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468.
11.
KucineN. Myeloproliferative neoplasms in children, adolescents, and young adults. Curr Hematol Malig Rep. 2020;15(2):141-148.
12.
TefferiAGuglielmelliPLarsonDRFinkeCWassieEAPieriL, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-2513;quiz 2615.
13.
BarbuiTThieleJGisslingerHKvasnickaHMVannucchiAMGuglielmelliP, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.
14.
MarchioliRFinazziGSpecchiaGCacciolaRCavazzinaRCilloniD, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
15.
PatronoCRoccaBDe StefanoV. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood. 2013;121(10):1701-1711.
